Despite the overwhelming evidence that has highlighted the clinical significance and prognostic implication of aberrant BCL9 expression in multiple cancer types, the molecular mechanisms underlying BCL9 activity in HCC remain elusive. This evidence concerns the gene BCL9 and hepatocellular carcinoma.